CVS Health
Coverage of CVS Health in the Nexus archive.
- CVS Health medicated wipes recalled over child safety concerns
CVS Health has recalled tens of thousands of medicated wipes sold in its stores due to concerns that children could access them and potentially be poisoned.
- Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs
Medicare has started covering obesity drugs for the first time, and companies like Walmart and CVS Health are assisting seniors in navigating this coverage.
- States seek to lower drug prices by targeting the companies that manage them for health plans
States are enacting laws to regulate pharmacy benefit managers (PBMs) like CVS to lower drug prices, requiring transparency and limiting their compensation. CVS and other PBMs are contesting these regulations through lawsuits and lobbying, arguing they help reduce costs by promoting generic drugs.
- States seek to lower drug prices by targeting the companies that manage them for health plans
States are enacting laws to regulate pharmacy benefit managers (PBMs) like CVS to lower drug prices, with Tennessee banning PBMs from operating retail pharmacies by 2028. CVS and other PBMs are contesting these regulations through legal action and advertising campaigns, arguing they help reduce drug costs by promoting generic medications.
- States seek to lower drug prices by targeting the companies that manage them for health plans
States are implementing laws to reduce drug prices by regulating pharmacy benefit managers (PBMs) like CVS, which oversee prescription coverage for insurers. Tennessee's law, set to take effect in 2028, prohibits PBMs from operating retail pharmacies, prompting a lawsuit from CVS. Over 60% of U.S. adults express concern about affording prescriptions, with states passing measures to limit PBM compensation and increase transparency.
- States seek to lower drug prices by targeting the companies that manage them for health plans
States are enacting laws to regulate pharmacy benefit managers (PBMs) like CVS to lower drug prices, with Tennessee banning PBMs from operating retail pharmacies by 2028. CVS has sued to avoid closing its pharmacies and spent millions opposing regulations, while a KFF poll highlights widespread public concern over medication affordability.
- States seek to lower drug prices by targeting the companies that manage them for health plans
States are enacting laws to regulate pharmacy benefit managers (PBMs) like CVS to lower drug prices, with Tennessee banning PBMs from operating retail pharmacies by 2028. CVS and other PBMs are contesting these regulations through lawsuits and advertising campaigns, arguing they help reduce drug costs by promoting generic medications.
- Healthy Returns: CVS Health executives on reducing healthcare's biggest pain points
CVS Health executives discuss using AI and other technologies to reduce administrative burdens in healthcare and deliver more proactive care experiences.
- When it comes to CVS proposal, Massachusetts needs more primary care – but without Mass General Brigham prices
Massachusetts will review a proposal to affiliate 37 CVS MinuteClinic locations with Mass General Brigham to address primary care shortages, with projected annual cost increases ranging from $13 million to $40 million. The plan aims to expand services at MinuteClinics to include preventive care and chronic disease management, potentially serving up to 120,000 adults.
- STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
The article discusses upcoming public visibility of drug prices under Trump's most-favored-nation deals, highlighting three new drugs (Baxfendy, Awiqli, and Veppanu). CVS Health is reintroducing Eli Lilly's obesity drug Zepbound to formularies and removing coverage restrictions on Lilly's new weight loss pill Foundayo.
- CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS Health will add Zepbound coverage starting October 1 and begin covering Eli Lilly's newly approved obesity treatment, Foundayo, on June 1. The moves expand drug plan accessibility for weight management medications.
- Your health app may be failing you
A study by CVS Health reveals that many older adults face challenges with digital health tools due to low digital health literacy, including confusing portals, privacy concerns, outdated devices, and spotty internet. Despite these barriers, 86% of Medicare-age adults remain open to using digital health tools if they are designed to match their comfort levels.
- CVS sues Tennessee over pharmacy benefit manager monopoly law
CVS Health sued Tennessee after the state passed a law banning pharmacy benefit managers (PBMs) from owning pharmacies, targeting CVS as the only company in Tennessee with both a PBM and physical pharmacies. The law aims to address disparities in drug reimbursement rates between affiliated and non-affiliated pharmacies, with state lawmakers calling it PBM reform. CVS claims the law is unconstitutional and will restrict patient access to medications.
- Deranged Luigi Mangione fangirl says she would kill her own pharmacist mom if she became a healthcare exec
Lena Weissbrot, 32, a Luigi Mangione fangirl, claimed she would kill her mother, a senior CVS Health manager, if her mother became a healthcare executive. The statement was made on Weissbrot's Instagram story following a report revealing her mother's role at the pharmacy chain.
- Luigi Mangione superfan who taunted his victim's family outside court is revealed to be the daughter of a senior CVS healthcare boss
A superfan of Luigi Mangione taunted the victim's family outside court, later revealed to be the daughter of a senior executive at CVS Health. The incident highlights tensions surrounding the case and corporate affiliations.
- Corporate America shrugging off economic uncertainty as earnings deliver
Corporate America is delivering strong earnings despite economic uncertainty, with 84% of S&P 500 companies topping estimates. Companies like Uber, Disney, and CVS Health are reporting positive results, while some others struggle. The earnings season is one of the best in 20 years.